Videos

Expert oncologist Alicia Morgans, MD, MPH, shares her hope for future improvements in metastatic castration-resistant prostate cancer management as the landscape continues to evolve.

Comprehensive insight on the real-world use of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management, given patient, disease, and logistical concerns.

Closing out her discussion on novel therapeutics in endometrial cancer, Ritu Salani, MD, MBA, shares excitement for ongoing evolutions within the treatment landscape.

Key opinion leader Alicia Morgans, MD, MPH, considers the role of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management.

Expert perspectives on the VISION and TheraP trials, which utilized lutetium Lu 177 vipivotide tetraxetan, also known as lutetium-177–PSMA-617, in the setting of metastatic castration-resistant prostate cancer.

Expert Ritu Salani, MD, MBA, reviews data from TROPiCS-03 and considers the potential role for antibody drug conjugates in patients with advanced endometrial cancer.

A brief review of clinical trial data from RAINBO and GY020, which tested adjuvant immunotherapy following radiation in patients with endometrial cancer.

Focused discussion on the CARD trial, which utilized cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.

Focused discussion on single-agent immunotherapy in patients with advanced endometrial cancer following data from the PHAEDRA and DOMENICA clinical trials.

Following her review of a patient case of metastatic castration-resistant prostate cancer, Alicia Morgans, MD, MPH, highlights the range of treatment options in this setting.

Expert perspectives on the RUBY and GY018 trials, which tested dostarlimab and pembrolizumab, respectively, in combination with chemotherapy in patients with advanced or recurrent endometrial cancer.

Expert oncologist Alicia Morgans, MD, MPH, shares details on the diagnosis and management of a patient with metastatic castration-resistant prostate cancer.

Sheng F. Cai, MD, PhD, discusses the results of the BEAT AML master trial in patients with acute myeloid leukemia.

Leslie Randall, MD, MAS, offers closing thoughts on the future trajectory of ovarian cancer treatment.

An expert gynecologic oncologist comments on recent revisions to FDA-approved indications for PARP inhibitors in the treatment of ovarian cancer.

Leslie Randall, MD, MAS, reviews recent long-term data on PARP inhibitors in the treatment of ovarian cancer.

Clinical insights on how to manage adverse events for patients with ovarian cancer who are receiving PARP inhibitors.

An expert on ovarian cancer discusses factors that influence PARP inhibitor selection, when to initiate maintenance therapy, and how to counsel patients on PARP inhibitors.

Leslie Randall, MD, MAS, reviews the available treatment options for BRCA-mutated advanced ovarian cancer.

An overview of guideline recommendations for molecular testing in ovarian cancer.

Leslie Randall, MD, MAS, presents the case of a 55-year-old woman with BRCA-mutated ovarian cancer and provides her initial impressions.

Rami Komrokji, MD, discusses the different systems of classifying myelodysplastic syndrome.

Mohamad Mohty, MD, PhD, discusses the growing role of bispecific antibodies for the treatment of multiple myeloma.

Mark J. Levis, MD, PhD, discusses the takeaways from the phase 3 BMT CTN 1506/MORPHO trial which evaluated maintenance gilteritinib after allogeneic stem cell transplant in patients with FLT3-ITD–positive acute myeloid leukemia.

Mark A. Socinski, MD, discusses his approach to managing toxicities related to osimertinib for patients with non–small cell lung cancer and EGFR mutations.

Bhagirathbhai R. Dholaria, MBBS, discusses updated findings from the TRIMM-2 trial of talquetamab and daratumumab for the treatment of relapsed/refractory multiple myeloma.

Yael Cohen, MD, discusses the main safety findings from the phase 1/2 RedirecTT-1 trial, which is evaluating the combination of teclistamab-cqyv and talquetamab for the treatment of patients with relapsed/refractory multiple myeloma.

Michael Wang, MD, discusses what led to the start of the phase 3 BRUIN MCL-321 trial for patients with mantle cell lymphoma.

Hope S. Rugo, MD, FASCO, discusses background and key findings from the phase 3 CAPItello-291 trial in breast cancer.

Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses her research on issues facing patients who need care for gynecologic cancers who have private insurance in the United States.